HR 941
117th Congress
House
Health
Advisory bodies
Blood and blood diseases
Cell biology and embryology
Congressional oversight
Government studies and investigations
Health programs administration and funding
Medical research
Organ and tissue donation and transplantation
Research administration and funding
TRANSPLANT Act of 2021
Introduced: February 8, 2021
Introduced by:
Matsui, Doris O.
Democratic
· California
See on congress.gov
Everywhere this bill has been
20 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 26, 2021
Became Public Law No: 117-15.
May 26, 2021
Signed by President.
May 20, 2021
Presented to President.
May 18, 2021
Message on Senate action sent to the House.
May 17, 2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S2550)
May 17, 2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S2550)
May 17, 2021
Passed Senate without amendment by Voice Vote.
May 17, 2021
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
Apr 19, 2021
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 15, 2021
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 415 - 2 (Roll no. 109). (text: 04/14/2021 CR H1752-1753)
Apr 15, 2021
Motion to reconsider laid on the table Agreed to without objection.
Apr 15, 2021
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 415 - 2 (Roll no. 109).(text: 04/14/2021 CR H1752-1753)
Apr 15, 2021
Considered as unfinished business. (consideration: CR H1829)
Apr 14, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Apr 14, 2021
DEBATE - The House proceeded with forty minutes of debate on H.R. 941.
Apr 14, 2021
Considered under suspension of the rules. (consideration: CR H1752-1754)
Apr 14, 2021
Mr. Pallone moved to suspend the rules and pass the bill.
Feb 9, 2021
Referred to the Subcommittee on Health.
Feb 8, 2021
Referred to the House Committee on Energy and Commerce.
Feb 8, 2021
Introduced in House
Votes taken on this bill
1
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| Apr 15, 2021 | House · vote #109 | On Motion to Suspend the Rules and Pass | Passed | 415–2 | See who voted → |
Plain-English summary
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021 or the TRANSPLANT Act of 2021
This bill modifies and reauthorizes through FY2026 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant.
The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments.
In addition, the Government Accountability Office must report on the regenerative medicine workforce.
What's happening now
Became Public Law No: 117-15.
Committees of jurisdiction
3